Amneal Pharmaceuticals, Inc. AMRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.05B+7.6% | $3.02B+8.0% | $2.93B+9.5% | $2.85B+9.8% | $2.83B+13.4% | ||
| $1.87B+4.3% | $1.91B+7.4% | $1.86B+7.1% | $1.78B+5.4% | $1.79B+11.0% | ||
| $1.18B+13.4% | $1.11B+9.1% | $1.08B+13.9% | $1.07B+18.0% | $1.04B+17.9% | ||
| 38.7%+2.0pp | 36.9%+0.4pp | 36.8%+1.4pp | 37.7%+2.6pp | 36.7%+1.4pp | ||
| $184.52M-3.6% | $186.18M-2.4% | $205.62M+12.6% | $203.37M+24.9% | $191.46M+16.3% | ||
| $547.4M+13.5% | $526.83M+10.6% | $509.06M+11.5% | $489.93M+8.6% | $482.13M+9.5% | ||
| —— | —— | —— | —— | —— | ||
| $7.06M+14.7% | $5.24M+463% | $5.24M-66.0% | $6.15M-57.1% | $6.15M-57.0% | ||
| $435.52M+20.8% | $394.1M+58.1% | $357.86M+90.6% | $376.32M+116% | $360.42M+126% | ||
| 14.3%+1.6pp | 13.1%+4.1pp | 12.2%+5.2pp | 13.2%+6.5pp | 12.7%+6.4pp | ||
| -$237.51M+4.9% | -$241.09M+6.8% | -$246.52M+3.9% | -$249.21M-3.0% | -$249.83M-10.0% | ||
| -$253.62M+16.1% | -$254.89M+16.2% | -$289.2M+7.0% | -$287.02M+1.1% | -$302.42M-13.9% | ||
| —— | —— | —— | —— | —— | ||
| $181.9M+214% | $139.21M+353% | $68.66M+156% | $89.3M+177% | $58M+155% | ||
| $584K-97.7% | $11.28M-40.2% | $11.04M-52.7% | $38.06M+116% | $25.58M+83.5% | ||
| $122.12M+1,036% | $72.06M+162% | $5.9M+103% | $3.38M+102% | -$13.05M+92.3% | ||
| 4%+4.5pp | 2.4%+6.6pp | 0.2%+7.1pp | 0.1%+6.8pp | -0.5%+6.3pp | ||
| $0.38+1,050% | $0.23+161% | $0.02+102% | $0.01+101% | -$0.04+94.5% | ||
| $0.39+1,075% | $0.23+161% | $0.02+102% | $0.01+101% | -$0.04+94.6% | ||
| 1.3B+3.1% | 1.3B+4.1% | 1.3B+15.1% | 1.3B+31.5% | 1.3B+58.1% | ||
| 1.3B+1.5% | 1.3B+1.4% | 1.2B+13.2% | 1.2B+31.3% | 1.2B+56.5% | ||
| -$304K+87.0% | $390K+100% | -$1.39M+98.6% | -$1.24M+98.7% | -$2.33M+97.6% | ||
| $6.43M+111% | -$6.59M+87.0% | -$18.26M+34.6% | -$50.4M-192% | -$59.42M-1,299% | ||
| -$237.51M+4.9% | -$241.09M+6.8% | -$246.52M+3.9% | -$249.21M-3.0% | -$249.83M-10.0% | ||
| —— | —— | $1.41M-54.5% | $7.12M+437% | -$1.4M+1.8% | ||
| $7.41M+11.8% | $7.63M+30.6% | $8.07M+63.1% | $7.6M+93.0% | $6.63M+71.9% | ||
| $16.75M+104% | $16.52M+40.2% | $5.53M-50.8% | $5.47M-54.0% | $8.23M+3.5% | ||
| $7.06M+14.7% | $5.24M+463% | $5.24M-66.0% | $6.15M-57.1% | $6.15M-57.0% | ||
| $3.05B+7.6% | $3.02B+8.0% | $2.93B+9.5% | $2.85B+9.8% | $2.83B+13.4% | ||
| $435.52M+20.8% | $394.1M+58.1% | $357.86M+90.6% | $376.32M+116% | $360.42M+126% | ||
| $435.52M+20.8% | $394.1M+58.1% | $357.86M+90.6% | $376.32M+116% | $360.42M+126% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $3.0B in revenue over the trailing twelve months, up 7.6% year over year.
- Is Amneal Pharmaceuticals, Inc. profitable?
- Amneal Pharmaceuticals, Inc. reported $122.1M in net income over the trailing twelve months, a 4.0% net margin.
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.
- What is Amneal Pharmaceuticals, Inc.'s earnings per share?
- Amneal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $0.38.
- Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
